GlassScriptPhysician profile
Edward A Minor
NPI 1447341979
$3,380.99
in general payments reported to CMS, 2019-2025
17 companies · $81.17 in 2025
The $81.17 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $578 · 2021: $355 · 2022: $642 · 2023: $906 · 2024: $339 · 2025: $81.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $785.94 | 2019-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $468.69 | 2019-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $348.30 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $342.17 | 2019-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $299.18 | 2019-2024 | Austedo, Uzedy, Austedo Xr |
| Alkermes, INC. | $283.33 | 2019-2024 | Aristada, Lybalvi |
| Allergan, INC. | $275.34 | 2019-2020 | |
| Lundbeck LLC | $207.30 | 2021-2025 | Rexulti |
| Indivior INC. | $111.21 | 2022-2023 | Perseris |
| Vanda Pharmaceuticals INC. | $66.45 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.12 | 2023-2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $35.94 | 2024-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $27.85 | 2025 | Cobenfy |
| Eisai INC. | $20.19 | 2020 | |
| Ironshore Pharmaceuticals INC. | $18.63 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $13.20 | 2022 | |
| Neuronetics, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Minor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.